Adding camrelizumab to neoadjuvant chemotherapy for early or locally advanced triple-negative breast cancer increased the pathological complete response rate to 56.8% compared to 44.7% with placebo. The study, involving 441 participants in China, showed consistent benefits across patient subgroups with a manageable safety profile. Grade 3 or higher adverse events were higher in the camrelizumab-chemotherapy group, and event-free survival and disease-free survival rates were slightly higher with camrelizumab. The authors concluded that the addition of camrelizumab significantly improved pathological complete response, but noted limitations such as short follow-up duration and potential limited generalizability. The study was supported by Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Source link
Camrelizumab Helpful Addition to Breast Cancer Treatment
